Phase II trial of gaboxadol [OV101] in patients with fragile X syndrome

Trial Profile

Phase II trial of gaboxadol [OV101] in patients with fragile X syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions
  • Acronyms ROCKET
  • Most Recent Events

    • 11 Jul 2018 According to an Ovid Therapeutics media release, Randi Hagerman is a principal investigator of this trial.
    • 11 Jul 2018 Status changed from planning to recruiting, as reported in an Ovid Therapeutics media release.
    • 08 May 2018 According to an Ovid Therapeutics media release, company presented three poster presentations, including posters describing the economic and clinical burden of this severe disorder at American Academy of Neurology in April
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top